Veradigm | MDRX - Gross Profit On Sales


Veradigm reported $83.44M in Gross Profit on Sales for its fiscal quarter ending in September of 2022.





Gross Profit On Sales Change Date
Alcidion AUD 21.02M 5.65M Dec/2025
Ambu A/S DKK 948M 1000K Mar/2026
Amplifon EUR 890.64M 787.47M Dec/2025
Cardinal Health USD 2.5B 101M Mar/2026
Centene USD 5.26B 3.12B Mar/2026
Charles River Laboratories USD 279.32M 7.36M Mar/2026
Cigna USD 6.08B 50.37B Mar/2026
Coloplast 4.74B 27M Dec/2025
Computer Programs Systems USD 35.62M 3.23M Dec/2025
Convatec Group USD 660.5M 348.95M Dec/2024
CVS Health USD 15.62B 2.06B Mar/2026
Diasorin EUR 186M 0 Mar/2026
Elevance Health USD 11.68B 889M Dec/2025
General Electric Aerospace USD 4.24B 439M Mar/2026
Gulf Medical Proj AED 46.22M 8.48M Mar/2025
Humana USD 4.82B 754M Jun/2025
IQVIA Holdings USD 1.07B 52M Mar/2026
Laboratory Of America USD 1.01B 20.6M Mar/2026
Maximus USD 342.26M 23.59M Mar/2026
McKesson USD 3.68B 143M Dec/2025
Med Life RON 628.26M 7.99M Sep/2025
Molina Healthcare USD 1.49B 292M Mar/2026
Omnicell USD 140.36M 10.04M Mar/2026
Oriola-kd EUR 40.2M 2.1M Sep/2025
Owens Minor USD 272.05M 20.92M Dec/2025
Quest Diagnostics USD 906M 33M Mar/2026
Rede D'or Sao Luiz BRL 3.22B 34.56M Mar/2026
Siemens Healthineers EUR 2.14B 66M Mar/2026
Sonova Holding CHF 1.28B 205.2M Dec/2025
Supermax Corporation Bhd MYR -143.15M 161.11M Sep/2025
UnitedHealth USD 18.49B 2.14B Dec/2025
Veeva Systems USD 678.61M 56.14M Mar/2026
Veradigm USD 83.44M 3.95M Sep/2022
Xerox USD 441M 15M Jun/2025